This clinical trial is focused on studying the effects of different doses of the anesthetic medication thiopental sodium during electroconvulsive therapy (ECT) for patients with major depressive disorder. Major depressive disorder, often referred to as depression, is a mental health condition characterized by persistent feelings of sadness and loss of interest. The trial aims to determine if using a lower dose of thiopental sodium during ECT can lead to a greater reduction in depressive symptoms compared to a higher dose.
Participants in the study will undergo six sessions of ECT, a treatment that involves sending small electric currents through the brain to trigger a brief seizure, which can help alleviate symptoms of depression. The study will compare the effects of a low dose versus a high dose of thiopental sodium on the reduction of depressive symptoms. Additionally, the study will observe other factors such as the duration of seizures, cognitive side effects, the total number of ECT sessions needed, length of hospital stay, awareness during anesthesia, and the risk of depression returning within a year after treatment.
The purpose of this study is to explore whether adjusting the dose of thiopental sodium can improve the outcomes of ECT for patients with major depressive disorder. The trial will provide valuable insights into optimizing ECT treatment to enhance its effectiveness and minimize potential side effects for individuals suffering from depression.



Sweden